ChemicalBook > Product Catalog > API > Hormones and the Endocrine System > Pancreatic hormone and blood sugar regulation > Metformin
Metformin Chemical Properties
- Melting point:199-200 °C
- Boiling point:229.23°C (rough estimate)
- Density 1.0743 (rough estimate)
- refractive index 1.5760 (estimate)
- pkapKa 2.8(H2O,t =32) (Uncertain)
- CAS DataBase Reference657-24-9(CAS DataBase Reference)
- EPA Substance Registry SystemImidodicarbonimidic diamide, N,N-dimethyl- (657-24-9)
- ToxicityLD50 oral in mouse: 1450mg/kg
Metformin Usage And Synthesis
- Usesnon-insulin dependent diabetes mellitus
- IndicationsMetformin (Glucophage) was used in Europe for many years before it was approved for use in the United States in 1995. Metformin is the only approved biguanide for the treatment of patients with NIDDM that are refractory to dietary management alone. Metformin does not affect insulin secretion but requires the presence of insulin to be effective. The exact mechanism of metformin’s action is not clear, but it does decrease hepatic glucose production and increase peripheral glucose uptake. When used as monotherapy, metformin rarely causes hypoglycemia.
- Biological FunctionsMetformin can lower free fatty acid concentrations by 10 to 30%. This antilipolytic effect may help to explain the reduction in gluconeogenesis through reduced levels of available substrate (65). When given as a monotherapy, metformin treatment does not lead to hypoglycemia, so it is better described as an antihyperglycemic agent rather than a hypoglycemic agent.
- General DescriptionMetformin is N,N-dimethylimidodicarbonimidic diamide,but can accurately and much more simply be namedas 1,1-dimethylbiguanide. Metformin is available, as its hydrochloridesalt, in tablets ranging in strengths from 500-mgto 1-g (Glucophage, numerous generics), extended-releasetablets (Fortamet, Glumetza), and an oral solution (Riomet);and in combinations with rosiglitazone (Avandamet),pioglitazone (Actoplus Met), glipizide (Metaglip, generics),glyburide (Glucovance), repaglinide (Prandimet), and mostrecently, sitagliptin (Janumet).
- General DescriptionMetformin, N,N-dimethylimidodicarbonimidicdiamide hydrochloride (Glucophage), is a bisguanidine.This class of agents is capable of reducing sugar absorptionfrom the gastrointestinal tract. Also, they can decrease gluconeogenesiswhile increasing glucose uptake by muscles andfat cells. These effects, in turn, lead to lower blood glucoselevels. Unlike the sulfonylureas, these are not hypoglycemicagents but rather can act as antihyperglycemics. This differencein nomenclature is caused by the inability of these agentsto stimulate the release of insulin from the pancreas. Often,metformin is coadministered with the nonsulfonylureas to improvethe efficacy of those agents.
- Clinical UseMetformin works best in patients with significant hyperglycemia and is often considered first-line therapy in the treatment of mild to moderate type II overweight diabetics who demonstrate insulin resistance. The United Kingdom Prospective Diabetes Study demonstrated a marked reduction in cardiovascular comorbidities and diabetic complications in metformintreated individuals. Metformin has also been used to treat hirsutism in individuals with polycystic ovarian syndrome and may enhance fertility in these women, perhaps by decreasing androgen levels and enhancing insulin sensitivity.
- Safety ProfilePoison by subcutaneous and intraperitoneal routes. Mildly toxic by parenteral route. Experimental teratogenic effects. Mutation data reported. When heated to decomposition it emits toxic fumes of NOx
- MetabolismMetformin is quickly absorbed from the small intestine. Bioavailability is from 50 to 60%, and the drug is not protein bound. Peak plasma concentrations occur at approximately 2 hours. The drug is widely distributed in the body and accumulates in the wall of the small intestine. This depot of drug serves to maintain plasma concentrations. Metformin is excreted in the urine, via tubular excretion, as unmetabolized drug with a half-life of approximately 2 to 5 hours; therefore, renal impairment as well as hepatic disease are contraindications for the drug.
- Company Name:Kangdi chemical (Hubei) Co., Ltd Gold
- Company Name:Nanjing Chemlin Chemical Co., Ltd
- Company Name:Hangzhou Yuhao Chemical Technology Co., Ltd
- Company Name:Beijing HuaMeiHuLiBiological Chemical
- Company Name:Shanghai TaoSu Biochemical Technology Co., Ltd.